TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: A systematic review and meta-analysis

Journal of the International AIDS Society

Volumn 19, Issue 1, 2016, Pages

  Ford, Nathan ^a   Matteelli, Alberto ^a,b   Shubber, Zara ^c   Hermans, Sabine ^d,e   Meintjes, Graeme ^d   Grinsztejn, Beatriz ^f   Waldrop, Greer ^g   Kranzer, Katharina ^h,i   Doherty, Meg ^a   Getahun, Haileyesus ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF BRESCIA   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^f Funda??o Oswaldo Cruz   (Brazil)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ RESEARCH CENTER BORSTEL   (Germany)

Author keywords

HIV AIDS; Hospitalization; Morbidity; Mortality; Tuberculosis

Indexed keywords

ISONIAZID;

ANTIVIRAL THERAPY; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; EUROPEAN; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENGTH OF STAY; LYMPH NODE BIOPSY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SCALE UP; SENSITIVITY ANALYSIS; STUDY; SYSTEMATIC REVIEW; TUBERCULOSIS; ADULT; CHILD; COMPLICATION; HOSPITAL MORTALITY; MALE;

ADULT; CHILD; HIV INFECTIONS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; TUBERCULOSIS;

EID: 84960157516     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.19.1.20714     Document Type: Review

References (34)

1. Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C, Murdoch DM, et al. Causes of death on antiretroviral therapy: A post-mortem study from South Africa. PLoS One. 2012; 7: E47542.
2. Cox JA, Lukande RL, Lucas S, Nelson AM, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev. 2010; 12: 183-94.
3. WHO. Global tuberculosis report. Geneva: World Health Organization; 2014.
4. Gupta-Wright A, Wood R, Bekker LG, Lawn SD. Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service. J Acquir Immune Defic Syndr. 2013; 64: 261-70.
5. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One. 2013; 8: E55824.
6. Cingolani A, Cozzi Lepri A, Castagna A, Goletti D, De Luca A, Scarpellini P, et al. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition. Clin Infect Dis. 2012; 54: 853-61.
7. Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: A systematic review and meta-Analysis. AIDS. 2015; 29: 1987-2002.
8. Namutebi AM, Kamya MR, Byakika-Kibwika P. Causes and outcome of hospitalization among HIV-infected adults receiving antiretroviral therapy in Mulago hospital, Uganda. Afr Health Sci. 2013; 13: 977-85.
9. Wen Y, Zhou Y, Wang W, Wang Y, Lu X, Sun CM, et al. Baseline factors associated with mortality within six months after admission among hospitalized HIV-1 patients in Shenyang, China. Intern Med. 2014; 53: 2455-61.
10. Melo-Uribe MA, Mantilla-Hernandez JC, Idarraga JD. HIV/AIDS-related opportunistic infections, based on analysis of autopsy cases. 103rd Annual Meeting of the United States and Canadian Academy of Pathology, USCAP; 2014 Mar 1-7; San Diego, CA.
11. Whitehorn J, Edwards SG, Cartledge JD, Miller RF. Outcome of HIV-infected patients transferred to a specialist inpatient unit. Int J STD AIDS. 2011; 22: 225-7.
12. Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes of hospital admission among people living with HIV worldwide: A systematic review and meta-Analysis. Lancet HIV. 2015; 2(10): 438-44.
13. Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950; 21: 607-11.
14. Miller J. The inverse of the Freeman-Tukey double arcsine transformation. Am Stat. 1978; 32: 138.
15. Fleiss JL. The statistical basis of meta-Analysis. Stat Methods Med Res. 1993; 2: 121-45.
16. UNAIDS. 15 by 15: A global target achieved. Geneva: UNAIDS; 2015.
17. WHO. Global update on HIV treatment. Geneva: WHO; 2015.
18. IeDEA and ART Cohort Collaborations, Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr. 2014; 65: E8-16.
19. Siedner MJ, Ng CK, Bassett IV, Katz IT, Bangsberg DR, Tsai AC. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: A meta-Analysis. Clin Infect Dis. 2015; 60: 1120-7.
20. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: Comparison with rates in the community. PLoS One. 2012; 7: E34156.
21. Study Group INSIGHT START, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373: 795-807.
22. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: Results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014; 14: 281-90.
23. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015; 373(9): 808-22.
24. Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: A stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013; 13: 852-8.
25. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007; 21: 1441-8.
26. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: A randomised double-blind, placebo-controlled trial. Lancet. 2014; 384: 682-90.
27. Gupta S, Granich R, Date A, Lepere P, Hersh B, Gouws E, et al. Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries. Int J Tuberc Lung Dis. 2014; 18: 1149-58.
28. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 Revision. Geneva: World Health Organization; 2010.
29. Meintjes G, Schoeman H, Morroni C, Wilson D, Maartens G. Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: A cross-sectional study. BMC Infect Dis. 2008; 8: 72.
30. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resourceconstrained settings: Informing urgent policy changes. Lancet. 2007; 369: 2042-9.
31. WHO. Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Geneva: WHO; 2013.
32. Hanrahan CF, Clouse K, Bassett J, Mutunga L, Selibas K, Stevens W, et al. The patient impact of point-of-care vs. laboratory placement of Xpert((R)) MTB/RIF. Int J Tuberc Lung Dis. 2015; 19: 811-6.
33. Van Den Handel T, Hampton KH, Sanne I, Stevens W, Crous R, Van Rie A. The impact of Xpert((R)) MTB/RIF in sparsely populated rural settings. Int J Tuberc Lung Dis. 2015; 19(4): 392-8.
34. WHO. WHO policy on collaborative TB/HIV activities guidelines for national programmes and other stakeholders. Geneva: WHO; 2012.